Yvonne Greenstreet
Showing 1–2 of 2 transcripts.
- Goldman Sachs30 min
Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
Alnylam Pharmaceuticals leverages a decade of RNA interference research to achieve a 55% clinical success rate and recently secured approval for Amvutra to treat hereditary transthyretin-mediated amyloidosis. Under CEO Yvonne Greenstreet, the company aims to become a top-five biotech leader by 2026 through a five-year strategy to deliver 25 clinical programs and expand into common diseases like hypertension. To reach this goal, Alnylam integrates AI-driven drug design with a culture of diversity and patient advocacy to de-risk development and target tissues beyond the liver, including the central nervous system.
- Milken Institute59 min
Finding a Cure for the Cost of Durable Therapies
Dan Mendelson, Yvonne Greenstreet, Joe Grogan, Michael Sherman, Mark Skinner, John Birch, Ian Kramer, Jupiter Lazmar
A panel of industry leaders, payers, and advocates highlighted the systemic friction between transformative gene therapies and traditional commercial models that rely on high-volume patient pools to amortize R&D costs. Participants detailed pricing pressures for one-time cures and chronic durable treatments while showcasing innovative risk-sharing agreements, such as Alnylam's outcomes-based pilot with Harvard Pilgrim Health Care, to manage financial exposure. Addressing these challenges, the group called for federal policy reform to eliminate "best price" disincentives and the adoption of flexible valuation frameworks that integrate patient-reported outcomes to prevent insurance affordability crises.